Search continues for a CMV vaccine for transplant recipients

The Lancet Haematology

Volumn 3, Issue 2, 2016, Pages e58-e59

  Boeckh, Michael ^a,b   Gilbert, Peter B ^a,b  

^a USA   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOMEGALOVIRUS VACCINE; GLYCOPROTEIN B; MIFAMURTIDE; STEROID; GANCICLOVIR; VACCINE;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIBODY RESPONSE; CELLULAR IMMUNITY; CYTOMEGALOVIRUS; GRAFT RECIPIENT; HUMAN; IMMUNE DEFICIENCY; IMMUNOSENESCENCE; NOTE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE FREE SURVIVAL; T LYMPHOCYTE; VACCINATION; VARICELLA ZOSTER VIRUS; VIREMIA; CYTOMEGALOVIRUS INFECTIONS;

CYTOMEGALOVIRUS INFECTIONS; GANCICLOVIR; HUMANS; TRANSPLANT RECIPIENTS; VACCINES;

EID: 84957846480     PISSN: None     EISSN: 23523026     Source Type: Journal    
DOI: 10.1016/S2352-3026(15)00286-0     Document Type: Note

References (10)

1. Boeckh M, Murphy WJ, Peggs KS Recent advances in cytomegalovirus: an update on pharmacologic and cellular therapies. Biol Blood Marrow Transplant 2015, 21:24-29.
2. Ljungman P The role of cytomegalovirus serostatus on outcome of hematopoietic stem cell transplantation. Curr Opin Hematol 2014, 21:466-469.
3. Zhou W, Longmate J, Lacey SF, et al. Impact of donor CMV status on viral infection and reconstitution of multifunction CMV-specific T cells in CMV-positive transplant recipients. Blood 2009, 113:6465-6476.
4. Kharfan-Dabaja MA, Boeckh M, Wilck MB, et al. A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis 2012, 12:290-299.
5. Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 2009, 15:1143-1238.
6. Griffiths PD, Stanton A, McCarrell E, et al. Cytomegalovirus glycoprotein-vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial. Lancet 2011, 377:1256-1263.
7. Plotkin S The history of vaccination against cytomegalovirus. Med Microbiol Immunol 2015, 204:247-254.
8. Nakamura R, La Rosa C, Longmate J, et al. Viraemia, immunogenicity, and survival outcomes of cytomegalovirus chimeric epitope vaccine supplemented with PF03512676 (CMVPepVax) in allogeneic haemopoietic stem-cell transplantation: randomised phase 1b trial. Lancet Haematol 2015, published online Dec 23. http://dx.doi.org/10.1016/S2352-3026(15)00246-X.
9. Freed DC, Tang Q, Tang A, et al. Pentameric complex of viral glycoprotein H is the primary target for potent neutralization by a human cytomegalovirus vaccine. Proc Natl Acad Sci U S A 2013, 110:E4997-E5005.
10. Haynes BF, Gilbert PB, McElrath MJ, et al. Immune-correlates analysis of an HIV-vaccine efficacy trial. N Engl J Med 2012, 366:1275-1286.